Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LAUSANNE, Switzerland & FRAMINGHAM, Mass. -- Businesswire -- Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk protein for tissue building and regeneration, announced today they have signed a co-development and option-to-acquire agreement.
This collaboration will further expand Galderma’s capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers. The novel platform harnesses the unique power of silk protein to enable immediate volume restoration and provide structure that facilitates new tissue generation.
“At Galderma, we’re committed to advancing dermatology through constant innovation and joining forces with other industry pioneers. Combining Galderma’s capabilities and scale with Sofregen’s novel silk platform represents a watershed moment for the aesthetics market through the development of a new category of biostimulator fillers designed to make an impact for healthcare professionals and their patients.”
BALDO SCASSELLATI SFORZOLINI GLOBAL HEAD OF RESEARCH & DEVELOPMENT GALDERMA
Sofregen’s pioneering silk technology combines silk protein with an HA carrier. Naturally derived, silk has been shown to have unique properties for tissue support and regeneration, making it particularly well suited for facial aesthetic procedures.
“Galderma is a world leader in dermatology, with decades of experience in delivering cutting edge innovation in facial aesthetics and we are thrilled to have them as a partner. This agreement highlights Sofregen’s dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space.”
JONATHAN T. HARTMANN CHIEF EXECUTIVE OFFICER SOFREGEN
Under the agreement, the companies will perform specified co-development activities related to a portfolio of novel silk-based biostimulator fillers, demonstrating Galderma’s commitment to deliver science-based innovation to the market. Galderma will also have an exclusive option to acquire Sofregen’s Silk Voice® as well as assets associated with its aesthetics business. This would grant Galderma all rights to the products being co-developed by the parties, as well as ownership of Sofregen’s silk technology platform in the aesthetic and dermatological field.
Galderma and Sofregen plan to launch the development programs for all products imminently, with both companies looking to get the collaboration underway and bring the products to market as quickly as possible.
About Sofregen’s Silk technology platform
Sofregen’s silk-based biostimulator filler consists of purified silk protein sponge particles mixed in cross-linked HA. The silk particles act as a scaffold and facilitate cellular infiltration; over time, the silk will be enzymatically degraded, replaced by newly generated tissue. Preclinical studies show that when a suspension of these particles is injected through a small gauge needle, it acts to facilitate durable cellular ingrowth and collagen production, while slowly bioresorbing over time. For more information: www.sofregen.com.
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.
About Sofregen Medical
Sofregen is a pioneer in soft tissue engineering with an advanced platform based on silk protein, also known as fibroin, which has been shown to have unique properties for tissue support and regeneration. Sofregen’s Silk platform is carefully engineered to match the biomechanics of soft tissue for immediate bulking and long-term tissue replacement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005995/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright (c) 코리아뉴스와이어, 무단복제 및 재배포 금지
- BTS 정국 탔던 ‘G바겐’ 보배드림에 매물로 등장
- 기아, The Kia EV9 세계 최초 공개
- JW 메리어트의 국내 첫 럭셔리 리조트 ‘JW 메리어트 제주 리조트 & 스파’ 3월 28일 공식 오픈
- 비즈니스북스 ‘나를 지켜내는 연습’ 출간
- 스마트북스, 신간 ‘국어머리 공부법’ 출간
- 효성 조현준 회장, 대한민국 경영자대상 수상
- 포스코인터내셔널, 생분해성 바이오플라스틱 리사이클링 사업에 도전
- 디랙스, 총상금 5000만원의 실내 트레드밀 마라톤 대회 ‘디랙스 인도어 마라톤’ 개최
- GS25, 퓨전 디저트 ‘크낭시에’ 2종 출시
- ‘제21회 대구국제안경전’ 4월 5일 개막… 안광학 신산업·신기술 교류의 장